Biogen brags of Phase III data for would-be Aubagio rival oral MS drug

Share this article:
A study published in the New England Journal of Medicine indicates that Biogen Idec's experimental MS drug, BG-12 is on track to make an impression. The study said patients taking the oral medication had a significantly lower annual relapse rate at two years when taking the drug two or three times a day, compared with placebo. The study did not show the drug had any significant impact on slowing disease progression.

Thursday's news brings the drug one step closer to its built-in fan base. It also comes a week after the FDA approved Sanofi's oral contender, Aubagio (teriflunomide). Phase III trials of Sanofi's therapy reduced the relapse rate among MS patients by about 30%. Industry watchers told MM&M at the time that the approval expanded patient options, but it was going to have a longer acceptance curve among physicians than BG-12, which has cultivated a level of pre-approval confidence with its safety and efficacy profile.

Ben Weintraub, director of research at the health analytics firm InThought, told MM&M at the time of Sanofi's Augbagio approval that this will translate into doctor preference for the Biogen Idec drug over rivals like Aubagio or Tysabri for second-line use when interferon and Copaxone fail.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.